

B21

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 49/00, G01N 31/00	A1	(11) International Publication Number: WO 99/20313 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/US98/22217 (22) International Filing Date: 20 October 1998 (20.10.98) (30) Priority Data: 60/062,922 20 October 1997 (20.10.97) US 60/076,985 5 March 1998 (05.03.98) US (71) Applicant: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors: RICHARDS-KORTUM, Rebecca; 6410 Walebridge Lane, Austin, TX 78712 (US). DREZEK, Rebekah; Dept. of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX 78712 (US). SMITH-PETER, Colin; Dept. of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX 78712 (US). ZULAGA, Andres, F.; Apartment I, 912 W 22 1/2 Street, Austin, TX 78705 (US). (74) Agent: LAND, John; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, 92037 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ACETIC ACID AS A CONTRAST AGENT IN REFLECTANCE CONFOCAL IMAGING OF TISSUE (57) Abstract <p>A method for using acetic acid as a contrast agent during reflectance confocal imaging of normal and neoplastic tissue, particularly epithelium. In one aspect, the invention includes a method of using acetic acid as a contrast agent for confocal imaging of cells, including applying acetic acid to the diagnostic tissue sample in sufficient concentration to induce a small scale alteration of the index of refraction of nuclei in the cells; and imaging such cells using a reflectance confocal imaging system.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

ACETIC ACID AS A CONTRAST AGENT IN REFLECTANCE CONFOCAL IMAGING OF TISSUE

TECHNICAL FIELD

5 The invention relates to methods and apparatus used for optical diagnosis of tissue abnormalities, and more particularly to enhancing detection of tissue abnormalities by reflectance confocal imaging of normal and neoplastic tissue, particularly epithelium.

BACKGROUND

10 Confocal microscopy is now established as a valuable tool for obtaining high resolution images and 3-D reconstructions of a variety of biological specimens. In particular, confocal microscopy has the capability to quickly provide information about the biochemical and morphological changes that occur as tissue becomes neoplastic.

 In reflectance confocal microscopy, a laser light beam is expanded to make optimal use of
15 the optics in the objective. Through an X-Y deflection mechanism, the laser beam is turned into a scanning beam, focused to a small excitation spot by an objective lens onto a specimen. Reflected light is captured by the same objective and, after conversion into a static beam by the X-Y deflection mechanism, is focused onto a photodetector. A confocal aperture (*e.g.*, a pinhole) is placed in front of the photodetector, such that the reflected light from points on the specimen that are not within the
20 focal plane (the so called "out-of-focus" light) where the laser beam was focused will be largely obstructed by the pinhole. In this way, out-of-focus information (both above and below the focal plane) is greatly reduced. This becomes especially important when dealing with thick specimens. The spot that is focused on the center of the pinhole is often referred to as the "confocal spot."

 A 2-D image of a small partial volume of the specimen centered around the focal plane
25 (referred to as an optical section) is generated by performing a raster sweep of the specimen at that focal plane. As the laser scans across the specimen, the analog light signal, detected by the photodetector, is converted into a digital signal, contributing to a pixel-based image displayed on

- 2 -

a computer monitor attached to the confocal microscope. The relative intensity of the light reflected from the laser "hit" point, corresponds to the intensity of the resulting pixel in the image (typically 8-bit grayscale). The plane of focus (Z-plane) is selected by a computer-controlled fine-stepping motor which moves the microscope stage up and down. Typical focus motors can adjust the focal plane in as little as 0.1 micron increments. A 3-D reconstruction of a specimen can be generated by stacking 2-D optical sections collected in series.

High resolution confocal imaging can be used to obtain near real-time reflected light images of human epithelial tissue *in vivo* with micron resolution. *In vivo* confocal imaging can provide information about subcellular morphologic and biochemical changes in epithelial cells which may be useful in the recognition and monitoring of epithelial precancers in organ sites such as the uterine cervix and oral mucosa. Much of the work demonstrating the potential of confocal microscopy to image cell morphology has been carried out in pigmented tissue where melanin within cells provided the confocal signal and image contrast. More recent work has demonstrated confocal microscopy has the ability to visualize structure in amelanotic cells as well. However, the level of native contrast between diagnostically important structures such as the nucleus and the remainder of the cell's contents can vary significantly among cell types due to differences in cell composition.

Indeed, a problem with most optical examination systems and techniques, including reflectance confocal microscopy, is obtaining suitable signals indicative of the property to be measured. Contrast agents have been commonly applied to tissue *in vitro* and *in vivo* to enhance the optical return signal of illuminated tissue and thus aid in the extraction of diagnostically useful information from the sample. For example, techniques are commonly used to highlight cellular structures when using light microscopy to examine tissue samples. On a more gross level, sensitive differentiation between normal tissue and neoplasia in various tissue sites has been recently demonstrated through the use of 5-aminolevulinic acid induced protoporphyrin IX fluorescence.

Acetic acid is routinely used during colposcopy, a procedure involving examination of the cervix *in situ* with a low power microscope, to enhance differences between normal and diseased regions of the cervical epithelium. Areas which may develop into cervical cancer undergo a transient whitening (acetowhitening) visible to the naked eye. While the mechanism behind this phenomenon

- 3 -

is not yet fully understood, it is commonly agreed that the higher nuclear density present in abnormal epithelium is a significant factor.

The inventors have determined that it would be desirable to provide a technique for by enhancing the return optical signal for a reflectance confocal microscopy system in a manner that
5 enhances the detection of abnormal tissue. The present invention provides such a technique.

SUMMARY

The invention includes use of acetic acid as a contrast agent during reflectance confocal imaging of normal and neoplastic tissue, particularly epithelium. More particularly, in one aspect,
10 the invention includes a method of using acetic acid as a contrast agent for confocal imaging of cells, including applying acetic acid to the diagnostic tissue sample in sufficient concentration to induce a small scale alteration of the index of refraction of nuclei in the cells; and imaging such cells using a reflectance confocal imaging system.

The details of one or more embodiments of the invention are set forth in the accompanying
15 drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIGS. 1(a) and 1(b) are scanned photographs of confocal images of MCF7 cells before (left)
20 and after (right) application of acetic acid.

FIGS. 2(a) and 2(b) are scanned photographs of phase contrast images of the same cells before (left) and after (right) application of acetic acid.

FIGS. 3(a) and 3(b) show reflected light confocal images near the surface of the epithelium (50 μm deep) and near the basement membrane (200 μm deep).

25 FIG. 4(a) shows an image of a colposcopically normal biopsy, pre-acetic acid.

FIG. 4(b) shows an image of a colposcopically normal biopsy, post-acetic acid.

FIG. 4(c) shows an image of a colposcopically abnormal biopsy, pre-acetic acid.

FIG. 4(d) shows an image of a colposcopically abnormal biopsy, post-acetic acid.

- 4 -

FIGS. 5(a) and 5(b) showing *in vivo* confocal image of oral cavity mucosa before (FIG. 5(a)) and after (FIG. 5(b)) addition of acetic acid.

DETAILED DESCRIPTION

5 Confirmation of Effect

The invention includes use of acetic acid as a contrast agent during reflectance confocal imaging of normal and neoplastic tissue, particularly epithelium. To examine the effects of acetic acid on reflectance at the cellular level, we acquired images of breast cancer cells with a conventional confocal microscope using 800 nm illumination (*e.g.*, from a Ti:Sapphire laser) and
10 providing 1 μ m spatial resolution. The cells, from the MCF7 early breast cancer cell line, were first imaged in their native state, and then again after the addition of a 6% acetic acid solution. Cell viability was confirmed after exposure to acetic acid through the trypan blue exclusion assay. An example of a suitable confocal microscopy system is set forth in C. Smithpeter, *et al.*, *Near real time confocal microscopy of in situ amelanotic cells: sources of signal, contrast agents, and limits of*
15 *contrast*, J. Biomed. Opt., 19__, which is hereby incorporated by reference.

FIGS. 1(a) and 1(b) are scanned photographs of confocal images of MCF7 cells before (left) and after (right) application of acetic acid. In the image of native cells, the nucleus is difficult to resolve. The addition of acetic acid causes a dramatic increase in the signal from the nuclei, resulting in increased signal and image contrast. From these images, it is evident that acetic acid dramatically
20 increases the signal from the nucleus. We have shown that spatial fluctuations in index of refraction provide image contrast in confocal images. In particular, spatial fluctuations which are small compared to the illuminating wavelength provide the greatest increase in signal due to back scattering.

FIGS. 2(a) and 2(b) are scanned photographs of phase contrast images of the same cells
25 before (left) and after (right) application of acetic acid. FIGS. 2(a) and 2(b) demonstrate that acetic acid induces small-scale index variations in the nucleus of a cell, possibly arising from the coagulation of nuclear proteins. These results illustrate that acetic acid can be an important contrast

- 5 -

agent for confocal imaging of epithelial cells by highlighting nuclear morphology, which can aid in the discrimination of normal and neoplastic cells.

We have also explored the ability of acetic acid as a contrast agent in more complex biological specimens. Images were obtained from cervical biopsies a few minutes after exposure to 5 6% acetic acid. Biopsies were obtained, snap frozen, stored, and prepared according to protocols described in an earlier paper (A. Mahadevan, *et al.*, *Study of the fluorescence properties of normal and neoplastic human cervical tissue*, *Lasers Surg. Med.* 13, 647-655 (1993)). FIGS. 3(a) and 3(b) show reflected light confocal images near the surface of the epithelium (50 μ m deep) and near the basement membrane (200 μ m deep). In both images, the outlines of cells are clearly visible, as well 10 as the cell nuclei. Images obtained before the addition of acetic acid demonstrated similar features; however, signal strength and image contrast were reduced (data not shown).

To demonstrate that confocal imaging using acetic acid to increase the optical return signal could be used to discriminate changes associated with neoplasia, we used the confocal system to obtain images of a colposcopically normal and a colposcopically abnormal biopsy from the same 15 patient before and after the addition of acetic acid. After confocal imaging, transverse frozen sections were cut and stained with hemotoxylin and eosin. Frozen sections were sent to an experienced pathologist for histologic examination. Pathologic diagnoses confirmed clinical impressions at the time of colposcopy.

Results are shown in FIGS. 4(a)–4(d). FIGS. 4(a) and 4(b) show images of the colpo- 20 scopically normal biopsy, and FIGS. 4(c) and 4(d) contains images of the colposcopically abnormal biopsy which contained a high grade cervical intraepithelial neoplasia. FIGS. 4(a) and 4(c) are pre-acetic acid images of the abnormal biopsy which show the cell outlines and an occasional nucleus. The pre-acetic acid images of the abnormal biopsy show increased reflectivity of both the cell membranes and the nuclei. In addition, the cells are more crowded and irregularly spaced. FIGS. 25 4(b) and 4(d) are post-acetic acid images which show increased signal from the nuclei in both the normal and abnormal biopsies.

Finally, we have used acetic acid as a contrast agent for *in vivo* imaging of the oral mucosa of a normal, male volunteer. Visibility of the nuclei was increased after the addition of acetic acid.

- 6 -

FIGS. 5(a) and 5(b) showing *in vivo* confocal image of oral cavity mucosa before (FIG. 5(a)) and after (FIG. 5(b)) addition of 6% acetic acid.

These results show that after the addition of acetic acid, images of tissue can be obtained which illustrate characteristic differences between normal and neoplastic tissue throughout the entire epithelial thickness. Without the application of acetic acid, it is difficult to distinguish the nucleus from the cytoplasm of a cell because of low contrast. Since we have achieved similar results using acetic acid on multiple cell lines (breast and cervical) and tissue types (cervical and oral mucosa) in both *in vitro* and *in vivo* situations, acetic acid should be useful for improving nuclear contrast in a variety of organ sites.

Another aspect of the invention is that, unlike most previous work in which images are obtained in real time but then enhanced via time intensive image processing techniques, we present images as they appear at the time of acquisition without any post-processing. These images are representative of what would be possible for clinical applications requiring near video rate imaging and demonstrate the promise of this emerging technology for aiding standard histopathologic diagnosis.

Preferred Method

Having demonstrated that acetic acid can produce measurable differences in optical images of cellular tissue which may be diagnostically useful, the following is the preferred method of embodying this discovery in practice:

- (1) Applying acetic acid to the diagnostic tissue sample in sufficient concentration to induce a small scale alteration of the index of refraction of nuclei in the cells. Typical concentrations of acetic acid are 1%-6%, but any medically safe concentration that produces the desired alteration in response is suitable.
- (2) Imaging such cells using a reflectance confocal imaging system.

- 7 -

A number of embodiments of the present invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. For example, other apparatus than that described can be used with the inventive method. Accordingly, other embodiments are within the scope of the following claims.

- 8 -

WHAT IS CLAIMED IS:

1. A method of using acetic acid as a contrast agent for confocal imaging of cells, comprising the steps of:
 - 5 (a) applying acetic acid to the diagnostic tissue sample in sufficient concentration to induce a small scale alteration of the index of refraction of nuclei in the cells; and
 - (b) imaging such cells using a reflectance confocal imaging system.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/22217

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 49/00; G01N 31/00 US CL :424/9.6 According to International Patent Classification (IPC) or to both national classification and IPC																									
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/1.11, 1.65, 1.37, 1.81, 9.1, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8; 562/1, 400, 607; 600/473 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, BIOSIS, MEDLINE, USPATFULL, EMBASE, CAPLUS																									
C. DOCUMENTS CONSIDERED TO BE RELEVANT																									
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
Y	US 5,842,995 A (MAHADEVAN-JANSEN et al) 01 December 1998, see entire document, especially, column 15, lines 25-42.	1																							
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																									
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td>*X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*B</td><td>earlier document published on or after the international filing date</td><td>*Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L</td><td>document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A</td><td>document member of the same patent family</td></tr><tr><td>*O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>*P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A	document member of the same patent family	*O	document referring to an oral disclosure, use, exhibition or other means			*P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																						
*B	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																						
*L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A	document member of the same patent family																						
*O	document referring to an oral disclosure, use, exhibition or other means																								
*P	document published prior to the international filing date but later than the priority date claimed																								
Date of the actual completion of the international search 04 JANUARY 1999		Date of mailing of the international search report 26 JAN 1999																							
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>D. Lawrence Jr</i> D. Jones Telephone No. (703) 308-1235																							